Skip to main content

Dietary Approaches to Lowering LDL-C

  • Chapter
  • First Online:
Prevention and Treatment of Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Multiple epidemiological, experimental, genetic, and interventional trials have unequivocally established that low-density lipoprotein (LDL) is a causal risk factor for the initiation and progression of atherosclerosis. LDL-cholesterol (LDL-C) is a key goal for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) according to international guidelines. To achieve this, the 2019 American College of Cardiology/American Heart Association Guideline on the primary prevention of cardiovascular disease emphasizes the importance of adopting a healthy dietary pattern. This guideline document suggests that rather than focus on specific micronutrients, it may be more important to consider dietary patterns for the prediction and mitigation of cardiovascular disease risk. Current evidence suggests that adopting a healthy dietary pattern that includes fruits, vegetables, whole grains, nuts, legumes and, optionally, low-fat dairy and fish, and reduced consumption of red and processed meats, is a useful approach to lowering LDL-C. Here, we briefly review the role of LDL in the genesis of atherosclerosis, the importance of lowering LDL-C for primary and secondary prevention of ASCVD, and approaches to LDL-C lowering with dietary interventions and medical therapy. This chapter also evaluates the current evidence of different dietary patterns such as the Dietary Approaches to Stop Hypertension (DASH) diet, the Mediterranean diet, and plant-based vegetarian diets, with a specific focus on their impact on LDL-C.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Boren J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27(5):473–83.

    Article  CAS  PubMed  Google Scholar 

  2. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis - update and therapeutic implications. Circulation. 2007;116(16):1832–44.

    Article  CAS  PubMed  Google Scholar 

  3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Perak AM, Ning H, de Ferranti SD, Gooding HC, Wilkins JT, Lloyd-Jones DM. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation. 2016;134(1):9–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–64.

    Google Scholar 

  6. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.

    Article  CAS  PubMed  Google Scholar 

  7. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–31.

    Article  CAS  PubMed  Google Scholar 

  8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.

    Article  CAS  PubMed  Google Scholar 

  9. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, et al. Randomized trial of cholesterol-lowering in 4444 patients with coronary-heart-disease – the Scandinavian Simvastatin Survival Study (4s). Lancet. 1994;344(8934):1383–9.

    Google Scholar 

  10. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.

    Article  CAS  PubMed  Google Scholar 

  11. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.

    Article  CAS  PubMed  Google Scholar 

  12. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.

    Article  CAS  PubMed  Google Scholar 

  13. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

    Article  CAS  PubMed  Google Scholar 

  14. Mills EJ, O’Regan C, Eyawo O, Wu P, Mills F, Berwanger O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of > 40 000 patients. Eur Heart J. 2011;32(11):1409–U138.

    Article  CAS  PubMed  Google Scholar 

  15. Harcombe Z, Baker JS, DiNicolantonio JJ, Grace F, Davies B. Evidence from randomised controlled trials does not support current dietary fat guidelines: a systematic review and meta-analysis. Open Heart. 2016;3(2):e000409.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Siri-Tarino PW, Chiu S, Bergeron N, Krauss RM. Saturated fats versus polyunsaturated fats versus carbohydrates for cardiovascular disease prevention and treatment. Annu Rev Nutr. 2015;35:517–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Rouhani MH, Rashidi-Pourfard N, Salehi-Abargouei A, Karimi M, Haghighatdoost F. Effects of egg consumption on blood lipids: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2018;37(2):99–110.

    Article  CAS  PubMed  Google Scholar 

  18. Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2015;102(2):276–94.

    Article  CAS  PubMed  Google Scholar 

  19. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6):S1–S122.

    Article  PubMed  Google Scholar 

  20. Griffin JD, Lichtenstein AH. Dietary cholesterol and plasma lipoprotein profiles: randomized-controlled trials. Curr Nutr Rep. 2013;2(4):274–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. US Department of Health and Human Services; US Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th ed. Washington, DC: US Dept of Health and Human Services; December 2015. http://www.health.gov/DietaryGuidelines. Accessed Aug 2020.

  22. Mensink RP, Zock PL, Kester ADM, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):146–55.

    Article  Google Scholar 

  23. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998;18(3):441–9.

    Article  CAS  PubMed  Google Scholar 

  24. Astrup A, Dyerberg J, Elwood P, Hermansen K, Hu FB, Jakobsen MU, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr. 2011;93(4):684–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hjerpsted J, Leedo E, Tholstrup T. Cheese intake in large amounts lowers LDL-cholesterol concentrations compared with butter intake of equal fat content. Am J Clin Nutr. 2011;94(6):1479–84.

    Article  CAS  PubMed  Google Scholar 

  26. Guasch-Ferre M, Satija A, Blondin SA, Janiszewski M, Emlen E, O’Connor LE, et al. Meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk factors. Circulation. 2019;139(15):1828–45.

    Article  PubMed  Google Scholar 

  27. Freeland-Graves JH, Nitzke S, Academy of Nutrition and Dietetics. Position of the academy of nutrition and dietetics: total diet approach to healthy eating. J Acad Nutr Diet. 2013;113(2):307–17.

    Article  PubMed  Google Scholar 

  28. Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein Bcontaining lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149.

    Google Scholar 

  29. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD003177.

    PubMed  Google Scholar 

  30. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363–79.

    Article  CAS  PubMed  Google Scholar 

  31. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb. 1992;12(8):911–9.

    Article  CAS  PubMed  Google Scholar 

  32. Hooper L, Al-Khudairy L, Abdelhamid AS, Rees K, Brainard JS, Brown TJ, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD011094.

    PubMed  Google Scholar 

  33. Mensink RP, Katan MB. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men. N Engl J Med. 1989;321(7):436–41.

    Article  CAS  PubMed  Google Scholar 

  34. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids – results of the OmniHeart randomized trial. JAMA. 2005;294(19):2455–64.

    Article  CAS  PubMed  Google Scholar 

  35. Liska DJ, Cook CM, Wang DD, Gaine PC, Baer DJ. Trans fatty acids and cholesterol levels: an evidence map of the available science. Food Chem Toxicol. 2016;98:269–81.

    Article  CAS  PubMed  Google Scholar 

  36. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Medical progress – trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601–13.

    Article  CAS  PubMed  Google Scholar 

  37. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):E563–E95.

    PubMed  PubMed Central  Google Scholar 

  38. Rosinger A, Herrick K, Gahche J, Park S. Sugar-sweetened beverage consumption among U.S. youth, 2011–2014. NCHS Data Brief. 2017(271):1–8.

    Google Scholar 

  39. Welsh JA, Sharma A, Cunningham SA, Vos MB. Consumption of added sugars and indicators of cardiovascular disease risk among US adolescents. Circulation. 2011;123(3):249–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Duffey KJ, Gordon-Larsen P, Steffen LM, Jacobs DR, Popkin BM. Drinking caloric beverages increases the risk of adverse cardiometabolic outcomes in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Clin Nutr. 2010;92(4):954–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Haslam DE, Peloso GM, Herman MA, Dupuis J, Lichtenstein AH, Smith CE, et al. Beverage consumption and longitudinal changes in lipoprotein concentrations and incident dyslipidemia in US adults: the Framingham Heart Study. J Am Heart Assoc. 2020;9(5):e014083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ventura EE, Davis JN, Goran MI. Sugar content of popular sweetened beverages based on objective laboratory analysis: focus on fructose content. Obesity (Silver Spring). 2011;19(4):868–74.

    Article  CAS  Google Scholar 

  43. Zhang YH, An T, Zhang RC, Zhou Q, Huang Y, Zhang J. Very high fructose intake increases serum LDL-cholesterol and total cholesterol: a meta-analysis of controlled feeding trials. J Nutr. 2013;143(9):1391–8.

    Article  CAS  PubMed  Google Scholar 

  44. Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, et al. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 2015;101(6):1144–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30–42.

    Article  CAS  PubMed  Google Scholar 

  46. Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165(10):1161–6.

    Article  CAS  PubMed  Google Scholar 

  47. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785–822.

    Article  PubMed  Google Scholar 

  48. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333(20):1308–12.

    Article  CAS  PubMed  Google Scholar 

  49. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78(8):965–78.

    Article  CAS  PubMed  Google Scholar 

  50. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Han S, Jiao J, Xu J, Zimmermann D, Actis-Goretta L, Guan L, et al. Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis. Sci Rep. 2016;6:31337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117–24.

    Article  CAS  PubMed  Google Scholar 

  53. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER 3rd, Lin PH, et al. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) trial. Am J Clin Nutr. 2001;74(1):80–9.

    Article  CAS  PubMed  Google Scholar 

  54. Harsha DW, Sacks FM, Obarzanek E, Svetkey LP, Lin PH, Bray GA, et al. Effect of dietary sodium intake on blood lipids – results from the DASH-Sodium trial. Hypertension. 2004;43(2):393–8.

    Article  CAS  PubMed  Google Scholar 

  55. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferroluzzi A, Helsing E, et al. Mediterranean diet pyramid – a cultural model for healthy eating. Am J Clin Nutr. 1995;61(6):1402s–6s.

    Article  CAS  PubMed  Google Scholar 

  56. Shen J, Wilmot KA, Ghasemzadeh N, Molloy DL, Burkman G, Mekonnen G, et al. Mediterranean dietary patterns and cardiovascular health. Annu Rev Nutr. 2015;35:425–49.

    Article  CAS  PubMed  Google Scholar 

  57. Vincent-Baudry S, Defoort C, Gerber M, Bernard MC, Verger P, Helal O, et al. The Medi-RIVAGE study: reduction of cardiovascular disease risk factors after a 3-mo intervention with a Mediterranean-type diet or a low-fat diet. Am J Clin Nutr. 2005;82(5):964–71.

    Article  CAS  PubMed  Google Scholar 

  58. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, et al. Effect of an indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet. 2002;360(9344):1455–61.

    Article  PubMed  Google Scholar 

  59. Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2019;3:CD009825.

    PubMed  Google Scholar 

  60. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90.

    Article  CAS  PubMed  Google Scholar 

  61. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34.

    Article  CAS  PubMed  Google Scholar 

  62. Hernáez Á, Castañer O, Goday A, Ros E, Pintó X, Estruch R, et al. The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk individuals: a randomized controlled trial. 2017;61(9):1601015.

    Google Scholar 

  63. Thorogood M, Carter R, Benfield L, McPherson K, Mann JI. Plasma lipids and lipoprotein cholesterol concentrations in people with different diets in Britain. Br Med J (Clin Res Ed). 1987;295(6594):351–3.

    Article  CAS  Google Scholar 

  64. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001–7.

    Article  CAS  PubMed  Google Scholar 

  65. Cooper RS, Goldberg RB, Trevisan M, Tsong Y, Liu K, Stamler J, et al. The selective lipid-lowering effect of vegetarianism on low-density lipoproteins in a crossover experiment. Atherosclerosis. 1982;44(3):293–305.

    Article  CAS  PubMed  Google Scholar 

  66. Mishra S, Xu J, Agarwal U, Gonzales J, Levin S, Barnard ND. A multicenter randomized controlled trial of a plant-based nutrition program to reduce body weight and cardiovascular risk in the corporate setting: the GEICO study. Eur J Clin Nutr. 2013;67(7):718–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Barnard ND, Cohen J, Jenkins DJA, Turner-McGrievy G, Gloede L, Jaster B, et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006;29(8):1777–83.

    Article  CAS  PubMed  Google Scholar 

  68. Jenkins DJA, Kendall CWC, Marchie A, Faulkner D, Vidgen E, Lapsley KG, et al. The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metab-Clin Exp. 2003;52(11):1478–83.

    Article  CAS  PubMed  Google Scholar 

  69. Jenkins DJA, Kendall CWC, Marchie A, Faulkner DA, Wong JMW, de Souza R, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290(4):502–10.

    Article  CAS  PubMed  Google Scholar 

  70. Yokoyama Y, Levin SM, Barnard ND. Association between plant-based diets and plasma lipids: a systematic review and meta-analysis. Nutr Rev. 2017;75(9):683–98.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sofi F, Dinu M, Pagliai G, Cesari F, Gori AM, Sereni A, et al. Low-calorie vegetarian versus Mediterranean diets for reducing body weight and improving cardiovascular risk profile CARDIVEG study (cardiovascular prevention with vegetarian diet). Circulation. 2018;137(11):1103–13.

    Article  PubMed  Google Scholar 

  72. Ferdowsian HR, Barnard ND. Effects of plant-based diets on plasma lipids. Am J Cardiol. 2009;104(7):947–56.

    Article  PubMed  CAS  Google Scholar 

  73. deLorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, et al. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease – insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol. 1996;28(5):1103–8.

    Article  CAS  Google Scholar 

  74. Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr. 1986;43(1):92–7.

    Article  CAS  PubMed  Google Scholar 

  75. Erdman JW, Comm AN. Soy protein and cardiovascular disease – a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation. 2000;102(20):2555–9.

    Article  CAS  PubMed  Google Scholar 

  76. Damasceno NRT, Apolinario E, Flauzino FD, Fernandes I, Abdalla DSP. Soy isoflavones reduce electronegative low-density lipoprotein (LDL-) and anti-LDL- autoantibodies in experimental atherosclerosis. Eur J Nutr. 2007;46(3):125–32.

    Article  CAS  Google Scholar 

  77. O’Neill B, Raggi P. The ketogenic diet: pros and cons. Atherosclerosis. 2020;292:119–26.

    Article  PubMed  CAS  Google Scholar 

  78. Paoli A. Ketogenic diet for obesity: friend or foe? Int J Environ Res Public Health. 2014;11(2):2092–107.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Retterstol K, Svendsen M, Narverud I, Holven KB. Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: a randomized controlled study. Atherosclerosis. 2018;279:52–61.

    Article  PubMed  CAS  Google Scholar 

  80. Bueno NB, de Melo ISV, de Oliveira SL, Ataide TD. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 2013;110(7):1178–87.

    Article  CAS  PubMed  Google Scholar 

  81. Dong T, Guo M, Zhang P, Sun G, Chen B. The effects of low-carbohydrate diets on cardiovascular risk factors: a meta-analysis. PLoS One. 2020;15(1):e0225348.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Mansoor N, Vinknes KJ, Veierod MB, Retterstol K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr. 2016;115(3):466–79.

    Article  CAS  PubMed  Google Scholar 

  83. Anton SD, Moehl K, Donahoo WT, Marosi K, Lee SA, Mainous AG 3rd, et al. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity (Silver Spring). 2018;26(2):254–68.

    Article  Google Scholar 

  84. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019;381(26):2541–51.

    Article  PubMed  Google Scholar 

  85. Wilkinson MJ, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab. 2020;31(1):92–104. e5

    Article  CAS  PubMed  Google Scholar 

  86. Most J, Gilmore LA, Smith SR, Han H, Ravussin E, Redman LM. Significant improvement in cardiometabolic health in healthy nonobese individuals during caloric restriction-induced weight loss and weight loss maintenance. Am J Physiol Endocrinol Metab. 2018;314(4):E396–405.

    Article  CAS  PubMed  Google Scholar 

  87. Lefevre M, Redman LM, Heilbronn LK, Smith JV, Martin CK, Rood JC, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009;203(1):206–13.

    Article  CAS  PubMed  Google Scholar 

  88. Kroeger CM, Klempel MC, Bhutani S, Trepanowski JF, Tangney CC, Varady KA. Improvement in coronary heart disease risk factors during an intermittent fasting/calorie restriction regimen: relationship to adipokine modulations. Nutr Metab (Lond). 2012;9(1):98.

    Article  CAS  Google Scholar 

  89. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.

    Article  CAS  PubMed  Google Scholar 

  90. Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. 2017;136(20):1878−+.

    Google Scholar 

  91. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001–9.

    Article  CAS  PubMed  Google Scholar 

  92. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.

    Article  CAS  PubMed  Google Scholar 

  93. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

Michael D. Shapiro: reports scientific advisory activities with Amgen, Esperion, and Regeneron as well as consultant activities with Novartis. Parag Anilkumar Chevli: declares no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael D. Shapiro .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chevli, P.A., Shapiro, M.D. (2021). Dietary Approaches to Lowering LDL-C. In: Wilkinson, M.J., Garshick, M.S., Taub, P.R. (eds) Prevention and Treatment of Cardiovascular Disease. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-78177-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-78177-4_13

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-78176-7

  • Online ISBN: 978-3-030-78177-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics